Skip to main content
CANN GROUP LIMITED logo

CANN GROUP LIMITED — Investor Relations & Filings

Ticker · CAN ISIN · AU000000CAN2 LEI · 529900XX42XELLXVQE42 ASX Manufacturing
Open in API
Filings indexed 729 across all filing types
Latest filing 2022-04-06 Regulatory Filings
Country AU Australia
Listing ASX CAN

About CANN GROUP LIMITED

https://www.canngrouplimited.com/

Cann Group Limited specializes in the cultivation, manufacture, and supply of medicinal cannabis products. The company focuses on providing pharmaceutical-grade cannabis for therapeutic use, utilizing advanced greenhouse technology and automated cultivation systems to ensure standardized quality and consistency. Its operations encompass the entire supply chain, from plant genetics and breeding to the production of finished medicinal products, including oils and dried flower. Cann Group serves healthcare professionals and patients through established distribution channels and maintains a focus on research and development to advance cannabinoid-based treatments. The company leverages large-scale production capabilities to meet growing demand in both domestic and international medicinal markets, emphasizing rigorous quality control and compliance with international pharmaceutical standards.

Recent filings

Filing Released Lang Actions
ODC manufacture permit granted for Mildura 2 pages 187.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 7 April 2022 regarding the granting of a manufacturing permit by the Office of Drug Control (ODC) to Cann Group Limited for its Mildura facility. The content focuses on regulatory approval and operational updates related to manufacturing permits and licensing. There are no financial statements, earnings data, or detailed financial analysis present. The document is relatively short (3344 characters) and serves as a regulatory and operational update rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a report publication announcement since it does not mention the release or availability of a report. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance updates that do not fit other specific categories.
2022-04-06 English
Evaluation and option agreement with GSK Consumer Healthcare 3 pages 229.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 6 April 2022 regarding an evaluation and option agreement between Cann Group Limited and GSK Consumer Healthcare. It details the terms of the agreement, the ongoing Phase 3 clinical trial, and potential commercialization plans. The content is focused on a business development update and partnership evaluation rather than financial results, regulatory filings, or management changes. It does not contain financial statements or detailed financial analysis, nor is it a report or transcript. The document is a corporate announcement about a commercial agreement and strategic partnership evaluation, which fits best under Capital/Financing Update (CAP) as it relates to potential commercialization and business development activities involving licensing and marketing rights.
2022-04-05 English
Appendix 3G - lapse of options 1 page 146.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 4 April 2022 regarding the lapse of options that were not exercised by holders. It mentions the number of options lapsed, exercise prices, and that an Appendix 3G will be lodged with the ASX. The content is a specific update on capital instruments (options) and does not contain financial statements or detailed financial analysis. The document length is short (2251 characters) and it is an announcement of a corporate action related to capital structure (options lapse). This fits the category of Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2022-04-03 English
Notification of cessation of securities - CAN 4 pages 24.6KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options (convertible securities) for Cann Group Limited. It provides specific information about the securities that have ceased, including ASX security codes, number of securities ceased, reasons for cessation, and dates. The document is an announcement about changes in the company's issued capital related to securities that have expired or ceased. It does not contain financial statements, management discussion, or detailed financial results. It is not a full report but a regulatory announcement about securities cessation. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-04-03 English
Satipharm CBD products get green light from UK FSA 2 pages 193.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 April 2022 regarding the UK Food Standards Agency's approval of Cann Group's Satipharm Advanced CBD products. It discusses regulatory approval and market opportunity but does not contain financial statements, earnings data, or detailed financial analysis. The document is relatively short (4734 characters) and serves as a news release about regulatory approval and business prospects rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about product approval and market impact, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2022-03-31 English
Notification of cessation of securities - CAN 4 pages 24.4KB
Regulatory Filings Classification · 95% confidence The document is a notification about the cessation (lapse) of certain securities (performance rights) for Cann Group Limited. It details the number of securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There is no financial data, earnings information, or management discussion. The document is an announcement related to changes in the company's securities, specifically the cessation of certain rights, which fits the category of Regulatory Filings (RNS) as it is a regulatory announcement about securities status changes but not a full financial report or capital raising event.
2022-03-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.